



PRESS RELEASE

ORABLOC® IN THE WORLD

- ✓ **UNITED STATES: NEW NATIONAL DISTRIBUTION CONTRACT SIGNED WITH DARBY DENTAL SUPPLY LLC**
- ✓ **THE FIRST ORDERS HAVE BEEN DELIVERED IN IRAQ AND IN KOSOVO**

Capua, 28 September 2015 – Orabloc® continues its commercial advance from West to East.

Pierrel Pharma S.r.l. (the “Company”) – a wholly owned subsidiary of **Pierrel S.p.A.** dedicated to the development, registration and licensing of new drugs and medical devices – announces to the market **the signature of a distribution agreement for Orabloc® (Articaina by Pierrel) with Darby Dental Supply Llc (“DDS”)**, the largest US national dental distributor operating in the segment for telemarketing and telesales of products for use by dental care professionals.

“This agreement will not be the last, for the United States, confirming that Orabloc® has convinced a market attentive to quality products” – stated Fabio Velotti, the sole Director of Pierrel Pharma, architect of the agreement with DDS, who continued: *“Darby Dental Supply is not the only news on the North American front. Thanks to the network attached to NDC Inc – which Pierrel Pharma is linked since 7 September last and that takes care of the supply chain for health products, the provision of logistics services and master distribution – two other local distributors have been activated today for Orabloc®, bringing to 16 the number of companies in the service of our commercial strategy. So let us welcome DDS and new members of NDC, which increase and qualify a prestigious sales network comprising Patterson Dental, Henry Schein, Benco Dental, DC Dental, Dental Health Products and Safco Dental”*.

Pierrel Pharma announces that, along with the agreement with DDS, they **began shipping in both Iraq and in Kosovo**, handling the first orders of Lidocaina Pierrel (Iraq) and Orabloc® (Kosovo). By the end of the year, the distribution of Orabloc® in **Serbia** will follow. The commitments made to the market have been thus fulfilled, as on 3 June it was announced that the dental anaesthetic by Pierrel would be available to new markets by the end of 2015. Pierrel Pharma also maintains firm prediction of starting the distribution of Orabloc® in Iran during the first quarter of 2016.

Fabio Velotti comments: *“The timing communicated to the market about the distribution in new markets has been respected thanks to the particular process of authorisation. These have come quickly thanks to the partnership - since the beginning of the process - with local distributors, companies previously identified by Pierrel. In this way, the time between registration and distribution was shortened.”*

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division). Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“DRR2.0”) and Integrated Clinical Development Services (“ICDS”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the



innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness.

Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Raffaele Petrone

E-mail: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult s.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665